The Schall Law Firm and DJS Law Group filed a securities class action lawsuit against Zoetis Inc. The legal action covers the period between January 14, 2025, and May 6, 2026.
The complaint alleges Zoetis failed to disclose significant challenges with several key product lines. It specifically cites weakening prescription growth for Librela following FDA safety warnings. The lawsuit also claims Trio, Apoquel, and Cytopoint lost market share to competitors.
Investors must file as lead plaintiff by the July 27, 2026, deadline. This litigation follows a first quarter where Zoetis missed earnings expectations.